GlassScriptPhysician profile
Snehal Shrivastava
NPI 1669882882
$1,000.16
in general payments reported to CMS, 2019-2025
15 companies · $251 in 2025
The $251 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $114 · 2021: $122 · 2022: $161 · 2023: $76.37 · 2024: $149 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $443 · Education: $34.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $442.62 |
| Education | $34.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $225.81 | 2019-2025 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $158.38 | 2019-2023 | Veltassa |
| Abiomed | $139.88 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.97 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $67.37 | 2024-2025 | |
| Amgen INC. | $66.53 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $55.63 | 2020-2024 | Acthar |
| Opko Pharmaceuticals, LLC | $40.98 | 2022-2025 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.62 | 2024 | Jardiance |
| Calliditas Therapeutics US INC. | $29.23 | 2023-2024 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $24.36 | 2025 | Ultomiris |
| Aurinia Pharma U.S., INC. | $23.04 | 2022 | |
| Glaxosmithkline, LLC. | $20.69 | 2024 | Jesduvroq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.98 | 2021 | |
| Travere Therapeutics, INC. | $10.69 | 2024-2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Snehal Shrivastava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.